-
公开(公告)号:US20170362242A1
公开(公告)日:2017-12-21
申请号:US15538902
申请日:2015-12-17
申请人: JIAN LIU , JOSEPH A. KOZLOWSKI , ABDUL-BASIT ALHASSAN , SOBHANA BABU BOGA , XIAOLEI GAO , DEODIAL GUY GUIADEEN , JYHSHING WANG , WENSHENG YU , JIAQIANG CAI , SHILAN LIU , DAHAI WANG , HAO WU , CHUNDAO YANG
发明人: JIAN LIU , JOSEPH A. KOZLOWSKI , ABDUL-BASIT ALHASSAN , SOBHANA BABU BOGA , XIAOLEI GAO , DEODIAL GUY GUIADEEN , JYHSHING WANG , WENSHENG YU , JIAQIANG CAI , SHILAN LIU , DAHAI WANG , HAO WU , CHUNDAO YANG
IPC分类号: C07D487/04 , A61K31/4985 , A61K31/5377 , C07D519/00
CPC分类号: C07D487/04 , A61K31/4985 , A61K31/5377 , A61K45/06 , A61P37/02 , C07D519/00
摘要: The present invention provides Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula (I), or pharmaceutically acceptable salts thereof, or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of Btk inhibitor compounds of Formula (I) in the treatment of Btk mediated disorders.
-
公开(公告)号:US20150299224A1
公开(公告)日:2015-10-22
申请号:US14434344
申请日:2013-10-03
申请人: W. Michael SEGANISH , William T. MCELROY , Stephanie BRUMFIELD , Jason R. HERR , Larry YET , Jinhai YANG , James P. HARDING, III , Ginny Dai HO , Deen B. TULSHIAN , Wensheng YU , Michael K.C. WONG , Brian J. LAVEY , Joseph A. KOZLOWSKI , MERCK SHARP & DOHME CORP.
发明人: W. MICHAEL SEGANISH , WILLIAM T. MCELROY , STEPHANIE BRUMFIELD , JASON R. HERR , LARRY YET , JINHAI YANG , JAMES P. HARDING, III , GINNY DAI HO , DEEN TULSHIAN , WENSHENG YU , MICHAEL K.C. WONG , BRIAN LAVEY , JOSEPH A. KOZLOWSKI
IPC分类号: C07D513/04 , C07D417/04 , C07D417/14 , A61K45/06 , C07D405/14 , A61K31/4436 , A61K31/444 , A61K31/506 , C07D401/04
CPC分类号: C07D513/04 , A61K31/4436 , A61K31/444 , A61K31/506 , A61K45/06 , C07D401/04 , C07D401/14 , C07D403/04 , C07D405/14 , C07D413/04 , C07D417/04 , C07D417/14
摘要: The present invention relates to compounds which modulate interleukin-1 (IL-1) receptor-associated kinase 4 (IRAK4) and are useful in the prevention or treatment of inflammatory, cell proliferative and immune-related conditions and diseases. Specifically, provided herein are inhibitors of IRAK4 of Formula I and pharmaceutical compositions comprising such inhibitors, as well as methods therewith for treating IRAK4-mediated or -associated conditions or diseases.
摘要翻译: 本发明涉及调节白细胞介素-1(IL-1)受体相关激酶4(IRAK4)并可用于预防或治疗炎症,细胞增殖和免疫相关病症和疾病的化合物。 具体地,本文提供了式I的IRAK4和包含这些抑制剂的药物组合物的抑制剂,以及其用于治疗IRAK4介导的或相关的病症或疾病的方法。
-